Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + nab-paclitaxel + gemcitabine for conversion therapy in unresectable locally advanced pancreatic cancer
ChiCTR2100046345Phase 2Recruiting
- Sponsor
- Renji Hospital
- Start
- Jul 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Renji Hospital. Primary endpoints: Surgical conversion rate and R0 resection rate. Started Jul 2021; status: recruiting.
02
Drugs
sintilimabpaclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2100046345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046345.